AMGN34 trade ideas
AMGN Attractive 237$ levelAMGN is at an attractive buying zone at 237$ per share. I see stock going up 5-10% where I would start taking profits. Using leverage or options would be a good play for this stock.
Technical Info:
Stock is at a confluence of several moving averages which will help rebound.
The stock is trading in sideways/up pattern and therefore is likely to continue or go up.
RSI is neither overbought or oversold. Once RSI gets above 50, high probability of stock going up 5%-10%.
AMGN BOUNCE Good reaction in Fibo clusters. Near strong dynamic support, makes sense to get in now. First thought is seeing this in $247 in the near future and then going back to the $258 resistance. My stop loss goes with the dynamic trendline acting as a support. I am in!
Potential AMGN long?Hi guys, I'm new to trading and this is my first post so could do with some feedback. Noticed a clear resistance and support line on the AMGN ticker. With a low RSI score does this stock have the potential for a breakout if it bounces off the support line again?
Understanding range highs and lows are all you need. #stocksBack on October 27th I made a post highlighting a potential reversal as we approached the range lows from back in June. Over the future months the stock tested the lows, found support, and is not heading toward highs. Range highs and lows and major support and resistance areas have value because they indicate where there is likely to be heavy order flow. In this case it AMGN reacted well and held the lows creating a great risk/reward opportunity.
NASDAQ:AMGN Possible Breakout Opportunity (Longer Term)I like the Weekly setup on this NASDAQ stock, the breakout target if reached would be near the Yearly R2 Pivot @ ~310
$AMGN - biotechHad a double bottom
Has nice reversal.
Positive indicators match others in biotech category
riding up to $258 - swing or options
Seems like a strong breakout for $AMGNSymbol: AMGN
AssetType: Common Stock
Name: Amgen Inc
Description: Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Exchange: NASDAQ
Currency: USD
Country: USA
Sector: Healthcare
Industry: Drug Manufacturers-General
Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
FullTimeEmployees: 23400
FiscalYearEnd: December
LatestQuarter: 2020-09-30
MarketCapitalization: 142916681728
EBITDA: 12647000064
PERatio: 19.7992
PEGRatio: 1.5407
BookValue: 18.781
DividendPerShare: 7.04
DividendYield: 0.0287
EPS: 12.399
RevenuePerShareTTM: 42.405
ProfitMargin: 0.2942
OperatingMarginTTM: 0.3757
ReturnOnAssetsTTM: 0.0945
ReturnOnEquityTTM: 0.6718
RevenueTTM: 24987000832
GrossProfitTTM: 19006000000
DilutedEPSTTM: 12.399
QuarterlyEarningsGrowthYOY: 0.049
QuarterlyRevenueGrowthYOY: 0.12
AnalystTargetPrice: 255.28
TrailingPE: 19.7992
ForwardPE: 13.7741
PriceToSalesRatioTTM: 5.5562
PriceToBookRatio: 12.4317
EVToRevenue: 6.4341
EVToEBITDA: 12.4492
Beta: 0.7616
52WeekHigh: 261.431
52WeekLow: 173.5108
50DayMovingAverage: 229.69
200DayMovingAverage: 238.9139
SharesOutstanding: 582169024
SharesFloat: 581126530
SharesShort: 6958047
SharesShortPriorMonth: 6912555
ShortRatio: 2.82
ShortPercentOutstanding: 0.01
ShortPercentFloat: 0.012
PercentInsiders: 0.188
PercentInstitutions: 77.988
ForwardAnnualDividendRate: 7.04
ForwardAnnualDividendYield: 0.0287
PayoutRatio: 0.3993
DividendDate: 2021-03-08
ExDividendDate: 2021-02-11
LastSplitFactor: 2:1
LastSplitDate: 1999-11-22
AMGN LONG compared with the DOWIn order to enhance your plays when it comes to options(stocks), it will help to compare the stock to its relative index it is in. This was a stock I happened to come across just doing some random backtesting and saw a nice 4hr candle that could potentially cause a reaction for more upside. I forgot about it and came back about 2weeks later and saw my area was triggered. We got a reaction to the upside exactly what I was looking for. The second entry came at a time when the indexs (SPX, US30, NAS100) were selling off, so I was looking for any divergence between the stock and its pair. As you can see, the DOW created a lower low basically running for stops while AMGN was holding structure. This was a very strong confirmation of this trade panning out because whenever the DOW would gain strength, it would push AMGN higher and that is seen through current price. The target price is $250 where lies a gap in the market so I am looking for that to get filled. Divergence in the market is when two correlating assets are doing opposite things. If you can spot a divergence aligned with any other confirmations you may have, the trade will most likely playout nicely
AMGEN keeps pressing along from BUY signal. ATH here we come!Follow up to the AMGN video post.
$AMGN has been going strong, other than the brief respite for the bulls.
Earnings run up should take us to .786 FIBO and perhaps past all-time highs?
Happy Trading, from CJ -- aka the greatest FURU.
To find out more about The Ultimate Stock Indicator on Tradingview, please check my public profile.
AMGN triangle break out If you follow me for a while, you know I like to play triangle patterns and somehow familiar with it. This one is also pretty easy to notice, however target is being blocked by the trendline resistance, be patient for entry 15 30 days play.
$AMGN - in a new trendAMGN has broken its down trend and is slowly snaking upwards. Watch for a pull back, reanalyze for entry for continued climb north.
AMGN - Bullish TriangleStill bouncing inside the setup as consolidation move. Waiting for the price to bounce outside.
ABC BullishAmgn fell from a rw at 239ish and put a damper on the prior rally..it seems to be recovering ..
Looks like amgn made some sideways movement with R overhead..
Possible stop under C..
Pick a good entry if you like this stock and trade safely..
Long term uptrend...(20 yr monthly) with turbulence as of late..trend are hard to change though..like a big steam ship...they can't stop on a dime..but they can eventually stop and turn around...
Not a recommendation
$AMGN - NR Picks Nov 22Amgen se dedica a descubrir, desarrollar, fabricar y ofrecer terapias humanas en todo el mundo. Se centra en las áreas de inflamación, oncología / hematología, salud ósea, enfermedades cardiovasculares, nefrología y neurociencia.
La compañía tuvo una reacción positiva a inicios de mes cuando presentó una actualización de su fármaco para la psoriasis, durante el mes el precio de la acción fue cayendo hasta estar cerca a los niveles pre-reacción.
Este retroceso se ve como una oportunidad para Amgen , recordemos que esta compañía es una de las mas importantes del sector. Creemos que el interés de los inversores durante el mes ha cambiado a compañías que están brindando actualizaciones sobre el desarrollo de la vacuna contra el COVID-19.
$AMGN - NR Picks Nov 22Amgen se dedica a descubrir, desarrollar, fabricar y ofrecer terapias humanas en todo el mundo. Se centra en las áreas de inflamación, oncología / hematología, salud ósea, enfermedades cardiovasculares, nefrología y neurociencia.
La compañía tuvo una reacción positiva a inicios de mes cuando presentó una actualización de su farmaco para la psoriasis, durante el mes el precio de la accion fue cayendo hasta estar cerca a los niveles pre-reacción.
Este retroceso se ve como una oportunidad para Amgen, recordemos que esta compañía es una de las mas importantes del sector. Creemos que el interes de los inversiores durante el mes ha cambiado a compañías que estan brindando actualizaciones sobre el desarrollo de la vacuna contra el COVID-19.
